Schizophrenia Market

Table of Content

1. INTRODUCTION
   1. Study Assumptions and Market Definition
   2. Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
   1. Market Overview
   2. Market Drivers
      1. Rising Incidences of Mental Illnesses Owing to Genetic Dispositions, Specific Chemical Imbalances in the Brain, Substance Abuse, and Psychosocial Variables
   3. Market Restraints
      1. Stigma and Discrimination
      2. High Treatment Costs
   4. Market Opportunities
      1. Increase in Focus of Governments and Health Care Organizations on Mental Health
   5. Market Trends
      1. Personalized Medicine Approaches
      2. Digital Health Integration
5. MARKET SEGMENTATION
   1. By Treatment
      1. Oral
      2. Injectable
   2. By Therapeutic Class
      1. Second-generation Antipsychotics
      2. Third-generation Antipsychotics
      3. Other Therapeutic Classes
   3. By Distribution Channel
      1. Hospital Pharmacies
      2. Retail Pharmacies
      3. Online Pharmacies
   4. By Key Geographic Regions
      1. North America
         1. United States
         2. Canada
         3. Mexico
      2. Europe
         1. Germany
         2. United Kingdom
         3. France
         4. Italy
         5. Spain
         6. Rest of Europe
      3. Asia Pacific
         1. China
         2. Japan
         3. India
         4. Australia
         5. South Korea
         6. Rest of Asia Pacific
      4. Middle East and Africa
         1. GCC
         2. South Africa
         3. Rest of Middle East and Africa
      5. South America
         1. Brazil
         2. Argentina
         3. Rest of South America
6. COMPETITIVE LANDSCAPE
   1. Company Profile
      1. AbbVie Inc.
      2. Allergan
      3. Astellas Pharma Inc.
      4. AVINEURO PHARMACEUTICALS
      5. Alkermes
      6. AstraZeneca
      7. Bristol-Myers Squibb Company
      8. Eli Lilly and Company
      9. Gedeon Richter plc
      10. H. Lundbeck A/S
      11. Johnson & Johnson Services, Inc.
      12. Merz Pharma
      13. Novartis AG
      14. Otsuka Holdings Co. Ltd.
      15. PsychoGenics Inc.
      16. Pfizer Inc.
      17. Sumitomo Dainippon Pharma Co. Ltd.
      18. VANDA PHARMACEUTICALS
   2. MARKET OPPORTUNITIES AND FUTURE TRENDS

Frequently Asked Questions

Q.1. What is the projected market value of the global Schizophreniamarket?

The global market of Schizophrenia is projected to reach USD 14,582.49 Mn by 2033.

Q.2. What is the estimated growth rate (CAGR) of the global Schizophreniamarket?

The global Schizophrenia market has an estimated annual growth rate of 4.4%.

Q.3. What are the recent trends of Schizophreniamarket?

Personalized medicine approaches and digital health integration are some of the major trends of the market that is projected to boost the market growth in the near future.

Q.4. Which are the top companies to hold the market share in Schizophrenia?

The major companies profiled in this report include AbbVie Inc., Allergan, Astellas Pharma Inc., AVINEURO PHARMACEUTICALS, Alkermes, AstraZeneca, Bristol-Myers Squibb Company, Eli Lilly and Company, Gedeon Richter plc, H. Lundbeck A/S, Johnson & Johnson Services, Inc., Merz Pharma, Novartis AG, Otsuka Holdings Co. Ltd., PsychoGenics Inc., Pfizer Inc., Sumitomo Dainippon Pharma Co. Ltd., VANDA PHARMACEUTICALS, among others.

Q.5. Which region is estimated to held highest CAGR inSchizophreniamarket?

North America is estimated to hold biggest share in the market for Schizophrenia.